Esbensen AJ, Schworer EK, Hartley SL
Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable medication is similar to existing weight loss medications like tirzepatide and semaglutide but has increased efficacy
For retatrutide specifically, as it remains an investigational medicine, any adverse events experienced within a clinical trial setting should be reported directly to the trial sponsor and principal investigator in accordance with the trial protocol
Rapid weight loss can also affect pelvic floor function
It works for single-use reconstitution where the entire vial is consumed within 24 hours
Sildenafil often has a shorter window, while tadalafil can last much longer